• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.08% Nasdaq Down0.35%

    OXiGENE, Inc. (OXGN)

    0.54 Down 0.02(3.57%) 3:59PM EST
    |After Hours : 0.54 0.00 (0.00%) 4:38PM EST
    ProfileGet Profile for:
    OXiGENE, Inc.
    701 Gateway Boulevard
    Suite 210
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-635-7000
    Fax: 650-635-7001
    Website: http://www.oxigene.com

    Index Membership:N/A
    Full Time Employees:13

    Business Summary 

    OXiGENE, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents to treat cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating gastrointestinal neuroendocrine tumors. The company also develops OXi4503 for patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. OXiGENE, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on OXiGENE, Inc.

    Key Executives 
    Dr. William D. Schwieterman M.D., 58
    Chief Exec. Officer, Pres, Director and Chairman of Nominating & Governance Committee
    Dr. David J. Chaplin B.Sc, M.Sc, Ph.D., 60
    Chief Scientific Officer and Director
    Mr. Matthew M. Loar , 53
    Chief Financial Officer
    Ms. Shari Annes ,
    Exec. Officer of Investor Relations
    Dr. Yuval Binur Ph.D.,
    Exec. VP of Financial
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders